Fresenius Kabi And Formycon Ally On Stelara Rival
German Firms Strike Global Licensing Agreement For FYB202 Ustekinumab Biosimilar
Fresenius Kabi and Formycon have announced a global licensing deal for the FYB202 ustekinumab proposed biosimilar rival to Stelara. The deal comes as Formycon has revealed plans to raise further funds to funnel into research and development through a fresh share issue.
You may also be interested in...
Who’s Hired? Sandoz Names Post-Spinoff Chair
Sandoz has announced the appointment of a chairman-designate ahead of its planned separation from parent company Novartis this year. Meanwhile, Canadian industry association the CGPA has also named a new chair and vice-chair, while Formycon has appointed a new CFO.
Stada And Alvotech Eye Potential EU Ustekinumab Nod This Year
Alvotech and Stada have indicated that they could receive an EMA opinion on their AVT04 Stelara biosimilar as early as the second half of 2023, after the agency confirmed acceptance of their ustekinumab filing.
Deal Watch: BMS Returning IL-12 Candidate To Frequent Partner Dragonfly
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.